2/6
12:44 pm
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.
2/6
09:47 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.
2/6
09:17 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.
2/5
12:51 pm
amgn
CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]
Low
Report
CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]
2/4
03:42 pm
amgn
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
Low
Report
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
2/4
02:48 pm
amgn
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance]
Low
Report
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance]
2/4
11:36 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.
2/4
09:16 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.
2/4
09:16 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Morgan Stanley from $304.00 to $309.00. They now have an "equal weight" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Morgan Stanley from $304.00 to $309.00. They now have an "equal weight" rating on the stock.
2/4
09:16 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $335.00 to $360.00. They now have an "outperform" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $335.00 to $360.00. They now have an "outperform" rating on the stock.
2/4
09:06 am
amgn
Amgen (NASDAQ:AMGN) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Amgen (NASDAQ:AMGN) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/4
08:43 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Leerink Partners from $305.00 to $355.00. They now have an "outperform" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Leerink Partners from $305.00 to $355.00. They now have an "outperform" rating on the stock.
2/4
07:04 am
amgn
Amgen (NASDAQ:AMGN) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Amgen (NASDAQ:AMGN) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
2/4
05:36 am
amgn
AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook [Yahoo! Finance]
Medium
Report
AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook [Yahoo! Finance]
2/4
12:06 am
amgn
Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges [Yahoo! Finance]
Medium
Report
Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges [Yahoo! Finance]
2/3
08:26 pm
amgn
Amgen outlines $37B–$38.4B 2026 revenue target as Repatha, EVENITY, and TEZSPIRE drive momentum [Seeking Alpha]
Medium
Report
Amgen outlines $37B–$38.4B 2026 revenue target as Repatha, EVENITY, and TEZSPIRE drive momentum [Seeking Alpha]
2/3
06:38 pm
amgn
Insulin Resistance Market Expected to Witness Strong Growth During the Forecast Period (2026-2036) | DelveInsight [Yahoo! Finance]
Medium
Report
Insulin Resistance Market Expected to Witness Strong Growth During the Forecast Period (2026-2036) | DelveInsight [Yahoo! Finance]
2/3
04:26 pm
amgn
Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025 [Yahoo! Finance]
Medium
Report
Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025 [Yahoo! Finance]
2/3
04:17 pm
amgn
Amgen quarterly results beat Street estimates on higher sales, lower tax rate [Yahoo! Finance Canada]
Medium
Report
Amgen quarterly results beat Street estimates on higher sales, lower tax rate [Yahoo! Finance Canada]
2/3
04:15 pm
amgn
Amgen in charts: Enbrel sales see highest Y/Y decline of 48% [Seeking Alpha]
Medium
Report
Amgen in charts: Enbrel sales see highest Y/Y decline of 48% [Seeking Alpha]
2/3
04:08 pm
amgn
Amgen quarterly results beat Street estimates on higher sales, lower tax rate [Yahoo! Finance]
Medium
Report
Amgen quarterly results beat Street estimates on higher sales, lower tax rate [Yahoo! Finance]
2/3
04:01 pm
amgn
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
High
Report
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
2/2
10:04 pm
amgn
Read the Decision [The New York Times]
Low
Report
Read the Decision [The New York Times]
2/2
01:03 pm
amgn
New Acute Myeloid Leukemia Hope: Amgen Acquires Dark Blue Therapeutics [Los Angeles Times (CA)]
Low
Report
New Acute Myeloid Leukemia Hope: Amgen Acquires Dark Blue Therapeutics [Los Angeles Times (CA)]
2/2
12:54 pm
amgn
Amgen Stock: Is Wall Street Bullish or Bearish? [Yahoo! Finance]
Low
Report
Amgen Stock: Is Wall Street Bullish or Bearish? [Yahoo! Finance]